It is also likely that glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists will play a greater role in the management of PCOS as these medications become ever more widely used for weight loss and the management of metabolic syndrome and diabetes. This evidence concerns the gene GIP and metabolic syndrome.